Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine functions by activating the mother’s immune system to generate protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, exactly when they are most vulnerable to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.

• Nearly 85% protection when immunised four weeks before birth
• Maternal antibodies passed through the placenta safeguard newborns from birth
• Protection achievable with 2-week gap before premature birth
• Vaccination during the third trimester still provides significant protection for infants

Compelling evidence from current research

The effectiveness of the RSV vaccine administered during pregnancy has been established through a comprehensive study carried out throughout England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month timeframe, providing strong and reliable data of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The scope of this study gives healthcare professionals and expectant parents with assurance in the vaccine’s established performance across different groups and contexts.

The results present a striking picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV during the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This marked difference highlights the vaccine’s vital importance in reducing the risk of serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.

Research approach and coverage

The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology captured real-world outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine performs when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and its risks

Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection produces inflammation deep within the lungs and airways, making it perilously hard for infected babies to feed and breathe adequately. Parents often witness their babies fighting for breath, their chests heaving as they try to pull adequate oxygen into their compromised lungs. Whilst most infants recover with palliative treatment, a small but significant proportion perish from respiratory syncytial virus complications each year, making vaccination as prevention a vital health service priority for protecting the youngest and most vulnerable people in our communities.

• RSV triggers inflammation in lungs, causing severe breathing difficulties in babies
• Nearly 50% of newborns contract the virus during their first few months alive
• Symptoms span from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
• Over 20,000 UK infants require serious hospital care for RSV each year
• Small numbers of infants succumb to RSV complications annually in the UK

Take-up rates and expert recommendations

Since the RSV vaccine programme commenced in 2024, health officials have stressed the significance of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies transferred to their babies through the placenta.

The communication from public health bodies remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of severe infection.

Regional variations in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These geographical variations demonstrate differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the overall statistics demonstrates consistently strong protection regardless of geographical location.

• NHS trusts deploying varied communication campaigns to engage with pregnant women
• Geographic variations in immunisation take-up across England necessitate strategic intervention
• Local healthcare systems adapting programmes to suit specific population needs

Practical implications and parent viewpoints

The vaccine’s impressive effectiveness provides tangible benefits for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this safeguarding intervention, the 80% drop in admissions represents thousands of infants protected against critical disease. Parents no more face the distressing scenario of watching their newborns gasping for air or struggle to eat, symptoms that mark critical RSV illness. The vaccine has markedly changed the picture of neonatal breathing health, providing expectant mothers a proactive tool to protect their youngest infants during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection led to profound brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab underscores the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to women in pregnancy navigating their third trimester, transforming what was once an unavoidable seasonal threat into a controllable health concern.